NASDAQ: CASI
Casi Pharmaceuticals Inc Stock

$2.50-0.09 (-3.47%)
Updated Feb 14, 2025
CASI Price
$2.50
Fair Value Price
N/A
Market Cap
$38.24M
52 Week Low
$2.05
52 Week High
$7.67
P/E
N/A
P/B
2.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.59
Operating Cash Flow
N/A
Beta
0.92
Next Earnings
Mar 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A

CASI Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CASI's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
D
Momentum
C
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CASI
Ranked
#64 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CASI news, forecast changes, insider trades & much more!

CASI News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CASI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CASI is good value based on its book value relative to its share price (2.76x), compared to the US Biotechnology industry average (4.77x)
P/B vs Industry Valuation
CASI's short-term assets ($47.15M) exceed its short-term liabilities ($14.74M)
Short-term Liabilities Financials
CASI's short-term assets ($47.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CASI due diligence checks available for Premium users.

Valuation

CASI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
-169.22x
Market
37.92x

CASI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.76x
Industry
4.77x
CASI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CASI's financial health

Profit margin

Revenue
$7.8M
Net Income
-$8.4M
Profit Margin
-107.7%

Assets to liabilities

Assets
$63.6M
Liabilities
$49.8M
Debt to equity
3.59
CASI's short-term assets ($47.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CASI's short-term assets ($47.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CASI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CASI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

CASI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CASIC$38.24M-3.47%N/A2.76x
CLNND$38.38M+5.48%-0.91x-9.30x
SRZNC$38.06M+9.44%-0.69x6.72x
ANVSD$37.67M+5.00%-0.71x5.33x
INKTC$37.56M+2.90%-2.50x-2.14x

Casi Pharmaceuticals Stock FAQ

What is Casi Pharmaceuticals's quote symbol?

(NASDAQ: CASI) Casi Pharmaceuticals trades on the NASDAQ under the ticker symbol CASI. Casi Pharmaceuticals stock quotes can also be displayed as NASDAQ: CASI.

If you're new to stock investing, here's how to buy Casi Pharmaceuticals stock.

What is the 52 week high and low for Casi Pharmaceuticals (NASDAQ: CASI)?

(NASDAQ: CASI) Casi Pharmaceuticals's 52-week high was $7.67, and its 52-week low was $2.05. It is currently -67.41% from its 52-week high and 21.95% from its 52-week low.

How much is Casi Pharmaceuticals stock worth today?

(NASDAQ: CASI) Casi Pharmaceuticals currently has 15,294,393 outstanding shares. With Casi Pharmaceuticals stock trading at $2.50 per share, the total value of Casi Pharmaceuticals stock (market capitalization) is $38.24M.

Casi Pharmaceuticals stock was originally listed at a price of $1,244.10 in Dec 31, 1997. If you had invested in Casi Pharmaceuticals stock at $1,244.10, your return over the last 27 years would have been -99.8%, for an annualized return of -20.55% (not including any dividends or dividend reinvestments).

How much is Casi Pharmaceuticals's stock price per share?

(NASDAQ: CASI) Casi Pharmaceuticals stock price per share is $2.50 today (as of Feb 14, 2025).

What is Casi Pharmaceuticals's Market Cap?

(NASDAQ: CASI) Casi Pharmaceuticals's market cap is $38.24M, as of Feb 17, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Casi Pharmaceuticals's market cap is calculated by multiplying CASI's current stock price of $2.50 by CASI's total outstanding shares of 15,294,393.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.